Anxiety disorders rank as the ninth leading cause of health-related disability and are characterized by high prevalence, chronicity, and comorbidity (Vos T, Abajobir AA, Abate KH, The Lancet 390:1211–59, 2017). According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), anxiety disorders encompass generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobias, and agoraphobia(Edition F, Am Psychiatric Assoc 21:591–643, 2013) While some individuals benefit from pharmacotherapy or psychotherapy, (Cuijpers P, Cristea IA, Karyotaki E, et al., World Psychiatry 15(3):245–58, 2016; Slee A, Nazareth I, Bondaronek P, et al., Lancet 393(10173):768–77, 2019) many individuals still suffer from treatment resistance and poor disease prognosis. Over the past two decades, numerous clinical trials have been conducted to explore more effective treatment options for anxiety disorders. Among these, transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) have emerged as promising, safe, and noninvasive neuromodulation techniques. However, current studies lack consensus on the optimal treatment protocols for TMS and tDCS. Further research is essential to refine stimulation parameters and enhance the clinical efficacy of these approaches for anxiety disorders. This chapter provides an overview of TMS and tDCS as potential treatments for anxiety disorders.